Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease
NAPA, Calif., July 19, 2023 (Newswire.com)
–
Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages of Alzheimer’s Disease.
Neurovations began enrolling patients in 2021 in advance of Eli Lilly’s recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer’s Disease.
“We are thrilled to be part of this vital research. Alzheimer’s Disease affects nearly 1 million people in my home state of California,” said Dr. Eric Grigsby. “This is a significant step forward in the fight against Alzheimer’s, and we are optimistic about the impact this treatment may have on the members of my community with this condition.”
Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research for pain and neurologic diseases, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience.
The TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, evaluated the safety and efficacy of donanemab, an investigational, amyloid-targeting therapy. Participants with early symptomatic Alzheimer’s disease were enrolled in the study, and those with confirmed presence of AD neuropathology completed their course of treatment with donanemab.
Neurovations Research was selected as a study site in 2021 and worked with Eli Lilly to contribute to this groundbreaking research. Dr. Grigsby’s expertise and passion for advancing treatments for neurodegenerative diseases and chronic pain have been instrumental in the success of this collaboration.
Key findings from the TRAILBLAZER-ALZ 2 study include:
● Nearly half (47%) of participants on donanemab showed no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to 29% of participants on placebo.
● Donanemab treatment slowed clinical decline by 35% compared to placebo, leading to a 40% reduction in the decline of activities of daily living.
These results have significant implications for the treatment of early symptomatic Alzheimer’s disease and have prompted Lilly to move forward with FDA approval and global regulatory submissions. Neurovations and Dr. Eric Grigsby’s involvement in this study have further enhanced the research community’s understanding of the potential benefits of donanemab in Alzheimer’s disease management.
“Alzheimer’s Disease affects an estimated 6.7 million Americans aged 65 and older. This first step is monumental on the path to a cure. We are thrilled to have been part of the study and sincerely hope to begin offering the treatment as soon as possible,” stated Dr Grigsby.
Contact Information:
Krista Clark
Marketing Director
7072529665
Original Source:
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease
NAPA, Calif., July 19, 2023 (Newswire.com)
–
Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages of Alzheimer’s Disease.
Neurovations began enrolling patients in 2021 in advance of Eli Lilly’s recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer’s Disease.
“We are thrilled to be part of this vital research. Alzheimer’s Disease affects nearly 1 million people in my home state of California,” said Dr. Eric Grigsby. “This is a significant step forward in the fight against Alzheimer’s, and we are optimistic about the impact this treatment may have on the members of my community with this condition.”
Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research for pain and neurologic diseases, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience.
The TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, evaluated the safety and efficacy of donanemab, an investigational, amyloid-targeting therapy. Participants with early symptomatic Alzheimer’s disease were enrolled in the study, and those with confirmed presence of AD neuropathology completed their course of treatment with donanemab.
Neurovations Research was selected as a study site in 2021 and worked with Eli Lilly to contribute to this groundbreaking research. Dr. Grigsby’s expertise and passion for advancing treatments for neurodegenerative diseases and chronic pain have been instrumental in the success of this collaboration.
Key findings from the TRAILBLAZER-ALZ 2 study include:
● Nearly half (47%) of participants on donanemab showed no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to 29% of participants on placebo.
● Donanemab treatment slowed clinical decline by 35% compared to placebo, leading to a 40% reduction in the decline of activities of daily living.
These results have significant implications for the treatment of early symptomatic Alzheimer’s disease and have prompted Lilly to move forward with FDA approval and global regulatory submissions. Neurovations and Dr. Eric Grigsby’s involvement in this study have further enhanced the research community’s understanding of the potential benefits of donanemab in Alzheimer’s disease management.
“Alzheimer’s Disease affects an estimated 6.7 million Americans aged 65 and older. This first step is monumental on the path to a cure. We are thrilled to have been part of the study and sincerely hope to begin offering the treatment as soon as possible,” stated Dr Grigsby.
Contact Information:
Krista Clark
Marketing Director
7072529665
Original Source:
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Jovive Health Receives LegitScript Certification for Medication-Assisted Treatment Services
Jovive Health is recognized with industry-leading certification for treating patients with opioid use disorder.
EMERYVILL…
Cooper Hues Develops Luxury Technology Platform
Cooper Hues is thrilled to announce a new product addition to the company’s portfolio: Cooper – a global, web-based, luxury services and assets platform
Cooper Logo
Cooper Hues Logo
LOS ANGELES, July 19, 2023 (Newswire.com)
–
The platform is home to a marketplace that hosts listings for luxury asset and service providers, providing customized account access to individual clients, concierge companies and corporate travel groups.
Cooper expands on the company’s proven track record in the luxury industry and is a global expansion for the Cooper Hues product portfolio beyond the private jet charter space. Cooper Hues’ venture into the technology space is aimed at filling a longstanding gap in the industry, whereby, sourcing, booking and reservation management is still a largely manual process. Designed with concierge, vendor and corporate partners in mind, Cooper enables enterprises to instantly increase their global footprint and streamline business operations, saving money and increasing their margins — all while reducing the agency’s overhead that is typically associated with sourcing, quote reviews and reservation management. The platform even includes a commission markup tool and multi-currency, secure payment gateways to make the process of sourcing, customizing and securing a reservation as efficient as possible.
Cooper’s state-of-the-art digital platform also enables independent clients to browse, book and manage their own lifestyle services. The company recognizes modern consumer behavior depicts a change in preferences, with a large majority of industry newcomers looking for more control over their booking experience. Clients have the option of performing one-time reservations or booking assets and services on a recurring subscription basis.
For those requiring more bespoke services, Cooper Hues provides an even higher tier of membership: the Cooper Verified status. Such membership includes ’24/7, 365′ Cooper concierge access with a dedicated Cooper agent. Cooper Verified agents deliver bespoke requests, deals and packages outside of existing marketplace options, and provide client access to ultra-premium categories like private jet club memberships, exclusive parties and more.
“It’s a game changer,” says founder and CEO Gal Ozery. “It does for luxury services what Airbnb did for holiday rentals and what Amazon did to everyday shopping. We combined every asset and service that high-end clients want into a single platform that supports various types of members. Everybody wins.”
Vendors and concierge companies can expect to reduce booking risks, payment delays and lack of data security with the digital storefront and partner services provided by Cooper’s platform. The platform aims to reduce their partners’ overall booking and operations costs by an estimated 10-20% — an overhead cost typically incurred by firms who do not leverage technology to source, quote and manage their client books.
Cooper Hues has already begun accepting new clientele and partners amidst the pre-launch, and is opening the books to more clients, vendors, corporate, and concierge companies ahead of the global launch.
For more information on Cooper, to become a vendor, concierge or corporate member, or to invest in Cooper Hues, go to https://www.cooperhues.com/.
Contact Information:
Esther Adeyemi
CMO
Belinda Brown
PR
19145231267
Original Source:
Cooper Hues Develops Luxury Technology Platform
The post Cooper Hues Develops Luxury Technology Platform first appeared on RSVTV news.
Beyoncé’s Featured Dancers Les Twins Partners With Kids Write Network to Promote Mental Health
Les Twins
Larry & Laurent Bourgeois for Kids Write Network
ATLANTA, July 19, 2023 (Newswire.com)
–
Kids Write Network’s “RISE for Mental Tour with Les Twins” (RMH) has received praise from educators, parents and students across North America during visits to schools, community centers and hospitals. The Kids Write Network (KWN) and world-renowned dancers Larry and Laurent Bourgeois, known as Les Twins, aim to raise awareness about mental health and improve access to treatment and services.
In November 2022, Les Twins collaborated with KWN to develop workshops for schools and received widespread attention, with over 500 schools seeking to host the RHM tour. Through the power of dance, Les Twins demonstrate how they use body movement to cope with mental struggles, promote empowerment and show resilience.
The U.S. leg of RMH will launch Oct. 16 in Atlanta at the end of the current world tour that features Les Twins and their breathtaking performances. KWN will also release its AI app, which helps users measure progress in their mental health journeys.
KWN is a scientifically developed and medically approved in-school program that combines positive psychology, neuroscience, literary and art disciplines and the KWN Scyibl six-step program to provide students the tools to understand and better communicate about their mental health. KWN has received recognition from Canadian Prime Minister Justin Trudeau, who recommends the KWN program to Canadian schools.
The ATL Year of the Youth initiative is the reason the U.S. debut of RMH will be in Atlanta. KWN, Les Twins and Atlanta want to ensure youth have all of the resources they need to thrive.
Atlanta is also home to music industry veteran and philanthropist Shanti Das’ nonprofit organization “Silence the Shame” (STS), dedicated to eliminating mental health stigma, and to reducing health disparities, and suicide rates among vulnerable populations. STS creates positive experiences, relationships, and environments, promoting positive youth development and empowering young people to prioritize their mental well-being. As an advocate for innovative solutions to engage in marginalized communities, STS is pleased to serve as an outreach partner for the RMH tour. “Mental health conditions are a public health issue in our community, and we are dedicated to offering tools to support good mental health for youth,” says Das. A live taping of the “Silence the Shame” podcast and KWN Les Twins demo is scheduled for Aug. 13, 2023.
Due to its dedication and commitment to leading independent schools in best practices around mental health, Atlanta’s Pace Academy is the first school on the RMH US tour. “Pace is thrilled to partner with Kids Write Network and Les Twins to support mental wellness, engage young people, and promote positivity, joy and art through this unique program. Mental health is a focus of Excellence in Every Endeavor, our school’s 2022-2027 strategic plan, and our community is honored to serve as the launch site for RISE for Mental Health’s U.S. tour,” states Fred Assaf, Head of School, Pace Academy.
Contact Information:
Kimiko Queguiner
board member, KWN
(404) 316-7642
Helen Georgaklis
Founder, Kids Write Network
Original Source:
Beyoncé’s Featured Dancers Les Twins Partners With Kids Write Network to Promote Mental Health
The post Beyoncé’s Featured Dancers Les Twins Partners With Kids Write Network to Promote Mental Health first appeared on RSVTV news.
Panoramic Health Propels Integrated Value-Based Care in Texas Through a Strategic Partnership With San Antonio Kidney Disease Center
Panoramic Health, the Largest Physician-Led CKCC Participant, Drives Integrated, Value-Based Care to Patients With CKD-ESRD in South Texas Through Its Partnership With San Antonio Kidney Disease Center
…
Glenmeadow Celebrates Groundbreaking of Phase II Renovations to Independent Retirement Living Community
Glenmeadow, a leading provider of senior retirement lifestyle options, is thrilled to announce the groundbreaking of an exciting new addition to its esteemed Life Plan Community.
…
The post Glenmeadow Celebrates Groundbreaking of Phase II Renovations to Independent Retirement Living Community first appeared on RSVTV news.
Reveal Lasers LLC Announces Acquisition of AgeJET Advanced Plasma Skin Therapy Device
AgeJET \u2014 Before & After Post 1 Treatment
LAS VEGAS, July 19, 2023 (Newswire.com)
–
Reveal Lasers LLC, a subsidiary of Reveal Lasers LTD, is pleas…
SimplyRFiD to Demonstrate Groundbreaking AIMS Eyewear Inventory Automation System at Vision Expo in Las Vegas
Revolutionizing the eyewear industry with state-of-the-art RFID technology and a virtual assistant for frame buying and inventory management.
AIMS …
ELYSIAN’s ‘CatWalk FurBaby’ Documentary Selected as Finalist at New York City International Fashion Film Festival
Festival Will Announce Winners at Gala on Sept. 7, 2023
‘CatWalk FurBaby’ Movie Poster
‘CatWalk FurBaby’ Movie Poster
NEW YORK, July 19, 2023 (Newswire.com)
–
CatWalk FurBaby, a 38-minute documentary on the eponymous event that kicked off New York Fashion Week this past February, has been selected as a finalist in this year’s New York City International Fashion Film Festival.
ELYSIAN, an international luxury lifestyle brand created to inspire and reflect the interests of women over 40, held the inaugural CatWalk FurBaby earlier this year with an all-star team of 10 fashion designers, 10 models and 10 animal rescues, all in one spectacular show.
“There is a beautiful irony in an ‘underdog’, headquartered in a small town in South Carolina, galvanizing trailblazing women from around the world, in fashion, philanthropy, business, and the environment, to kick off New York Fashion Week in an unforgettable show benefiting animal welfare,” said ELYSIAN Publisher Karen Floyd, who served as the film’s executive producer.
“In a city used to heavy hitters like Vogue and MTV, it is an incredible privilege to be considered for such an amazing award. I’m so proud of our team, who spent countless hours of hard work putting the event and production of the documentary into the limelight. For me personally, it validates ELYSIAN’s ethos in connecting with more and more women across the globe. Women inspiring women.”
The New York City International Fashion Film Festival will be held Sept. 6 and 7; winners will be announced at a gala on Sept. 7.
CatWalk FurBaby partnered with the BISSELL Pet Foundation to distribute grant money to the participating rescues. With nearly 6,000 shelter and rescue partners, this national foundation is committed to ending pet homelessness and finding a loving home for every pet, impacting 665,000 pets since its inception in 2011.
“With so many pets at risk in shelters across the country, BISSELL Pet Foundation was honored to partner with ELYSIAN on the inaugural CatWalk FurBaby event to bring awareness to our lifesaving work, as well as the incredible work of 10 deserving shelters,” said Cathy Bissell, founder of BISSELL Pet Foundation. “We are thrilled the documentary was selected as a finalist in this year’s New York City International Fashion Film Festival and hope it will do even more to spread the message that the best place to find your next pet is at your local animal shelter.”
DRC Ventures, headed by the multifaceted powerhouse Dr. Christina Rahm, was the event’s title sponsor. Rahm and her husband Clayton Thomas served as co-producers of the film.
Rahm, the visionary founder of DRC Ventures — a company whose mission is to create sustainable solutions that challenge the status quo creatively, scientifically, and artistically — walked the runway alongside her models during CatWalk FurBaby’s second half, unveiling the Enviremware line from Merci Dupre Clothiers. The ultimate in luxury eco-fashion and protection, this innovative nano-biotech skin-coating technology offers a barrier against hazardous toxins that could threaten your health without sacrificing style.
“For DRC Ventures and me personally, the mission is to lead the world to better solutions,” Rahm said. “Everyone’s talking about sustainability. That’s fine, but that’s not enough. Our higher potential is to help our species and the world evolve into greatness, letting go of fear, and instead leaving a meaningful legacy for future generations.”
CatWalk FurBaby will return to New York Fashion Week in fall 2024.
For more information, visit https://readelysian.com.
Contact Information:
Jason Spencer
Director of Public Relations
+18643161122
Original Source:
ELYSIAN’s ‘CatWalk FurBaby’ Documentary Selected as Finalist at New York City International Fashion Film Festival
The post ELYSIAN’s ‘CatWalk FurBaby’ Documentary Selected as Finalist at New York City International Fashion Film Festival first appeared on RSVTV news.